Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/Takeda G protein-coupled receptor 5 (TGR5) signal transduction. The incretin glucagon-like peptide 1 (GLP-1) is mainly produced by L cells in the gut and regulates postprandial blood glucose. Changes in gut microbiota composition and function have been observed in obesity and type 2 diabetes (T2D). Meanwhile, the function and rhythm of GLP-1 have also been affected in subjects with obesity or T2D. Therefore, it is necessary to discuss the link between the gut microbiome and GLP-1. In this review, we describe the interaction between GLP-1 and the gut microbiota in metabolic diseases. On the one hand, gut microbiota metabolites stimulate GLP-1 secretion, and gut microbiota affect GLP-1 function and rhythm. On the other hand, the mechanism of action of GLP-1 on gut microbiota involves the inflammatory response. Additionally, we discuss the effects and mechanism of various interventions, such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery, on the crosstalk between gut microbiota and GLP-1. Finally, we stress that gut microbiota can be used as a target for metabolic diseases, and the clinical application of GLP-1 receptor agonists should be individualized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., et al. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.75 · Cited by 5,634
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
Short chain fatty acids in human large intestine, portal, hepatic and venous blood
Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., & Macfarlane, G. T. (1987) · Gut · doi:10.1136/gut.28.10.1221 · Cited by 3,119
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952 · cited 4×
“Specifically, the abundance of some butyrate-producing bacteria (such as the phylum Firmicutes and genus Bifidobac terium ) was reduced, while Gram-negative bacteria were relatively enriched such as the phyla Bacteroidetes and Proteobacteria (30, 31).”
BackgroundInfluentialTurnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Artificial sweeteners induce glucose intolerance by altering the gut microbiota
Suez, J., Korem, T., Zeevi, D., Zilberman-Schapira, G., Thaiss, C. A., Maza, O., Israeli, D., Zmora, N., Gilad, S., Weinberger, A., et al. (2014) · Nature · doi:10.1038/nature13793 · Cited by 2,067 · cited 1×
“Specifically, the abundance of some butyrate-producing bacteria (such as the phylum Firmicutes and genus Bifidobac terium ) was reduced, while Gram-negative bacteria were relatively enriched such as the phyla Bacteroidetes and Proteobacteria (30, 31).”
BackgroundProbiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059
Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans
Sender, R., Fuchs, S., & Milo, R. (2016) · Cell · doi:10.1016/j.cell.2016.01.013 · Cited by 2,050
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 1×
“On the one hand, secondary BAs activate Takeda G protein-coupled receptor 5 (TGR5) on intestinal L cells to stimulate GLP-1 secretion (70, 71).”
BackgroundHuman gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880 · cited 1×
“For example, RYGB surgery decreased Firmicutes and Archaea and increased Gammapro teobacteria (90).”
BackgroundShin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
The Integrative Human Microbiome Project
The Integrative HMP (iHMP) Research Network Consortium, Proctor, L. M., Creasy, H. H., Fettweis, J. M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G. A., Snyder, M. P., Strauss, J. F., et al. (2019) · Nature · doi:10.1038/s41586-019-1238-8 · Cited by 1,381
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
O’Toole, P. W., & Jeffery, I. B. (2015) · Science · doi:10.1126/science.aac8469 · Cited by 1,202
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice
Sharon, G., Cruz, N. J., Kang, D.-W., Gandal, M. J., Wang, B., Kim, Y.-M., Zink, E. M., Casey, C. P., Taylor, B. C., Lane, C. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.004 · Cited by 1,182
Circadian physiology of metabolism
Panda, S. (2016) · Science · doi:10.1126/science.aah4967 · Cited by 1,092 · cited 1×
“Circadian rhythms refer to physiological changes in an organism’s activities that occur almost every 24 hours, also known as the biological clock (118).”
BackgroundDiet and feeding pattern affect the diurnal dynamics of the gut microbiome
Zarrinpar, A., Chaix, A., Yooseph, S., & Panda, S. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.11.008 · Cited by 926
Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways
Bellono, N. W., Bayrer, J. R., Leitch, D. B., Castro, J., Zhang, C., O’Donnell, T. A., Brierley, S. M., Ingraham, H. A., & Julius, D. (2017) · Cell · doi:10.1016/j.cell.2017.05.034 · Cited by 910
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901 · cited 1×
“The composition and proportion of gut microbiota are affected by genes [FXR (20)], lifestyle [diet (21)], drugs [antibiotics (22)], aging (23), etc.”
BackgroundTremaroli, V., Karlsson, F., Werling, M., Ståhlman, M., Kovatcheva-Datchary, P., Olbers, T., Fändriks, L., le Roux, C. W., Nielsen, J., & Bäckhed, F. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.009 · Cited by 757
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741
Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion
Yadav, H., Lee, J.-H., Lloyd, J., Walter, P., & Rane, S. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.452516 · Cited by 709
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · cited 2×
“Interestingly, the colon produces high levels of SCFAs and contains many L cells (64).”
BackgroundHost variables confound gut microbiota studies of human disease
Vujkovic-Cvijin, I., Sklar, J., Jiang, L., Natarajan, L., Knight, R., & Belkaid, Y. (2020) · Nature · doi:10.1038/s41586-020-2881-9 · Cited by 614
Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., & Nobili, V. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12758 · Cited by 471 · cited 1×
“Intake of Lactobacillus reuteri improved GLP-1 and insulin secretion in people with glucose (85).”
BackgroundRole of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418 · cited 1×
“In summary, gut microbiota plays an important role in human health and disease, such as T2D [reviewed in references (27, 28)].”
BackgroundSelf-citationComplex Carbohydrate Utilization by the Healthy Human Microbiome
Cantarel, B. L., Lombard, V., & Henrissat, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028742 · Cited by 378 · cited 1×
“The human genome encodes fewer than 20 enzymes to digest complex carbohydrates (62), so some carbohydrate polymers (dietary fibers) that are neither digested nor absorbed in the small intestine will be fermented to SCFAs by gut microbiota through carbohydrate-active enzymes in the gastrointestinal…”
BackgroundFrom gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators
Han, H., Yi, B., Zhong, R., Wang, M., Zhang, S., Ma, J., Yin, Y., Yin, J., Chen, L., & Zhang, H. (2021) · Microbiome · doi:10.1186/s40168-021-01093-y · Cited by 292
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Freeland, K. R., & Wolever, T. M. S. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509991863 · Cited by 275
Simon, M.-C., Strassburger, K., Nowotny, B., Kolb, H., Nowotny, P., Burkart, V., Zivehe, F., Hwang, J.-H., Stehle, P., Pacini, G., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2690 · Cited by 253
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · cited 1×
“However, EECs increased the incretion of GLP-1 after sensing LPS as compensation (41).”
BackgroundProbiotic intervention has strain-specific anti-inflammatory effects in healthy adults
Kekkonen, R. A., Lummela, N., Karjalainen, H., Latvala, S., Tynkkynen, S., Järvenpää, S., Kautiainen, H., Julkunen, I., Vapaatalo, H., & Korpela, R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2029 · Cited by 223 · cited 1×
“Probiotic interventions have strain-specific anti-inflammatory effects on healthy adults (111).”
BackgroundLeveraging diet to engineer the gut microbiome
Wolter, M., Grant, E. T., Boudaud, M., Steimle, A., Pereira, G. V., Martens, E. C., & Desai, M. S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00512-7 · Cited by 211 · cited 1×
“The composition and proportion of gut microbiota are affected by genes [FXR (20)], lifestyle [diet (21)], drugs [antibiotics (22)], aging (23), etc.”
BackgroundModulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice
Lee, H., Lee, Y., Kim, J., An, J., Lee, S., Kong, H., Song, Y., Lee, C.-K., & Kim, K. (2018) · Gut Microbes · doi:10.1080/19490976.2017.1405209 · Cited by 203
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism
Choi, H., Rao, M. C., & Chang, E. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00452-2 · Cited by 192
Jia, L., Li, D., Feng, N., Shamoon, M., Sun, Z., Ding, L., Zhang, H., Chen, W., Sun, J., & Chen, Y. Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-07335-0 · Cited by 179
Wang, L., Li, P., Tang, Z., Yan, X., & Feng, B. (2016) · Scientific Reports · doi:10.1038/srep33251 · Cited by 165 · cited 1×
“The GLP-1 RA liraglutide, but not saxagliptin (129), changed the overall structure of the gut microbiota, especially some bacteria related to glucolipid metabolism and intestinal inflammation (130, 131).”
BackgroundHolscher, H., Taylor, A., Swanson, K., Novotny, J., & Baer, D. (2018) · Nutrients · doi:10.3390/nu10020126 · Cited by 126 · cited 1×
“An almond-based low carbohydrate diet consumption significantly increased the relative abundance of SCFA-producing bacteria Roseburis and Ruminococcus in human gastrointestinal microbiota (83, 84), as well as the GLP-1 concentration (84).”
BackgroundVildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., & Wang, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184735 · Cited by 124 · cited 1×
“Similarly, DPP-4 inhibitor (PKF-275-055 or vildagliptin) treatment was reported to significantly decrease Firmicutes/Bacteroidetes ratios and increase butyrate-producing bacteria in diabetic and obese mice, similar to metformin (143, 144).”
BackgroundSelf-citationMüller, M., Hermes, G. D. A., Emanuel E., C., Holst, J. J., Zoetendal, E. G., Smidt, H., Troost, F., Schaap, F. G., Damink, S. O., Jocken, J. W. E., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1704141 · Cited by 120
Lindgren, O., Mari, A., Deacon, C. F., Carr, R. D., Winzell, M. S., Vikman, J., & Ahrén, B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0366 · Cited by 111
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84 · cited 1×
“On the other hand, secondary BAs activate the farnesoid X receptor (FXR) to inhibit GLP-1 secretion (40, 72).”
BackgroundSanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0199-6 · Cited by 66
Ying, X., Rongjiong, Z., Kahaer, M., Chunhui, J., & Wulasihan, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1088187 · Cited by 47
Hemmer, A., Maiter, D., Buysschaert, M., & Preumont, V. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.007 · Cited by 29 · cited 1×
“This phenomenon is a state of GLP-1 resistance (114).”
Background
Cited by
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“While the brain does produce GLP-1, most circulating GLP-1 is gut-derived [110,111].”
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Jang, A.-R., Jung, D.-H., Lee, T.-S., Kim, J.-K., Lee, Y.-B., Lee, J.-Y., Kim, S.-Y., Yoo, Y.-C., Ahn, J.-H., Hong, E.-H., et al. (2024) · Nutrition · doi:10.1016/j.nut.2024.112565 · Cited by 20
Metadata
- Authors
- Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2024-01-16
- Volume
- 15
- Issue
- 1
- Pages
- e0203223-e0203223
- ISSN
- 2150-7511 (ISSN-L)
- OpenAlex
- W4389373504
- Cited by
- 150
- References
- 54
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.